Compare Stocks: CNTB, SABS, ABEO, and QTTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.57 -0.4%	$6.27	$4.00 ▼ $7.65	$319.66M	1.33	1.25 million shs	2.72 million shs
CNTB Connect Biopharma	$1.28 -0.8%	$2.13	$1.06 ▼ $3.82	$81.24M	-0.23	1.88 million shs	1.27 million shs
QTTB Q32 Bio	$10.54 -2.9%	$14.66	$1.72 ▼ $23.57	$323.30M	0.21	559,201 shs	972,323 shs
SABS SAB Biotherapeutics	$3.51 +0.3%	$3.66	$1.85 ▼ $5.15	$318.45M	0.53	282,728 shs	1.97 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-0.36%	+2.96%	-9.14%	-3.47%	-1.24%
CNTB Connect Biopharma	-0.78%	-37.25%	-47.97%	-36.00%	-22.14%
QTTB Q32 Bio	-2.95%	-5.05%	-33.46%	-11.43%	+488.83%
SABS SAB Biotherapeutics	+0.29%	+2.93%	-7.14%	-12.25%	+36.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$5.57 -0.4%	$6.27	$4.00 ▼ $7.65	$319.66M	1.33	1.25 million shs	2.72 million shs
CNTB Connect Biopharma	$1.28 -0.8%	$2.13	$1.06 ▼ $3.82	$81.24M	-0.23	1.88 million shs	1.27 million shs
QTTB Q32 Bio	$10.54 -2.9%	$14.66	$1.72 ▼ $23.57	$323.30M	0.21	559,201 shs	972,323 shs
SABS SAB Biotherapeutics	$3.51 +0.3%	$3.66	$1.85 ▼ $5.15	$318.45M	0.53	282,728 shs	1.97 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-0.36%	+2.96%	-9.14%	-3.47%	-1.24%
CNTB Connect Biopharma	-0.78%	-37.25%	-47.97%	-36.00%	-22.14%
QTTB Q32 Bio	-2.95%	-5.05%	-33.46%	-11.43%	+488.83%
SABS SAB Biotherapeutics	+0.29%	+2.93%	-7.14%	-12.25%	+36.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.80	Moderate Buy	$21.00	277.02% Upside
CNTB Connect Biopharma	2.75	Moderate Buy	$7.29	469.20% Upside
QTTB Q32 Bio	2.86	Moderate Buy	$31.00	194.12% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	241.88% Upside

Current Analyst Ratings Breakdown

Latest CNTB, SABS, ABEO, and QTTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	ABEO Abeona Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $30.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$17.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/16/2026	QTTB Q32 Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/16/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
9/15/2026	CNTB Connect Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/14/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/7/2026	QTTB Q32 Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/3/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/3/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	QTTB Q32 Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$34.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	54.72	N/A	N/A	$2.94 per share	1.89
CNTB Connect Biopharma	$60K	1,343.36	N/A	N/A	$0.75 per share	1.71
QTTB Q32 Bio	$53.74M	5.84	$1.47 per share	7.16	$3.41 per share	3.09
SABS SAB Biotherapeutics	$1.32M	241.95	$0.34 per share	10.24	$3.18 per share	1.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	3.51	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)

Latest CNTB, SABS, ABEO, and QTTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
CNTB Connect Biopharma	0.01	2.37	2.37
QTTB Q32 Bio	N/A	20.30	20.30
SABS SAB Biotherapeutics	0.01	9.22	9.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CNTB Connect Biopharma	58.72%
QTTB Q32 Bio	31.32%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
CNTB Connect Biopharma	22.60%
QTTB Q32 Bio	34.46%
SABS SAB Biotherapeutics	7.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	226	57.18 million	53.12 million	Optionable
CNTB Connect Biopharma	64	62.97 million	48.74 million	Optionable
QTTB Q32 Bio	22	29.77 million	19.51 million	N/A
SABS SAB Biotherapeutics	86	90.99 million	84.26 million	Not Optionable

CNTB, SABS, ABEO, and QTTB Headlines

Recent News About These Companies

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 10, 2026 | seekingalpha.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Rating of "Moderate Buy" by Brokerages

September 5, 2026 | marketbeat.com

SAB BIO to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.

August 26, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and SAB Biotherapeutics (SABS)

August 8, 2026 | theglobeandmail.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

August 6, 2026 | globenewswire.com

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

July 15, 2026 | finance.yahoo.com

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

July 12, 2026 | theglobeandmail.com

SAB Biotherapeutics, Inc.: Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes

July 7, 2026 | finanznachrichten.de

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

July 7, 2026 | globenewswire.com

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

July 6, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | finance.yahoo.com

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

May 29, 2026 | globenewswire.com

Citigroup initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 23, 2026 | msn.com

Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 7.01%

May 21, 2026 | aaii.comA

SAB Biotherapeutics Inc SABS

May 20, 2026 | morningstar.comM

Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation

May 20, 2026 | msn.com

SAB Biotherapeutics Signs Manufacturing Pact for SAB-142

May 16, 2026 | theglobeandmail.com

We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully

May 16, 2026 | finance.yahoo.com

SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...

May 12, 2026 | finance.yahoo.com

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, SABS, ABEO, and QTTB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$5.57 -0.02 (-0.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.66 +0.09 (+1.67%)

As of 09/18/2026 07:58 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Connect Biopharma NASDAQ:CNTB

$1.28 -0.01 (-0.78%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.29 +0.01 (+0.78%)

As of 09/18/2026 07:55 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Q32 Bio NASDAQ:QTTB

$10.54 -0.32 (-2.95%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.89 +0.35 (+3.32%)

As of 09/18/2026 07:30 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

SAB Biotherapeutics NASDAQ:SABS

$3.51 +0.01 (+0.29%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.50 0.00 (-0.14%)

As of 09/18/2026 07:30 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, SABS, ABEO, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, SABS, ABEO, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, SABS, ABEO, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, SABS, ABEO, and QTTB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Connect Biopharma NASDAQ:CNTB

Q32 Bio NASDAQ:QTTB

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, SABS, ABEO, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, SABS, ABEO, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, SABS, ABEO, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB, SABS, ABEO, and QTTB Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

Connect Biopharma NASDAQ:CNTB

Q32 Bio NASDAQ:QTTB

SAB Biotherapeutics NASDAQ:SABS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools